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AKI are limited. [3] Myoglobin-induced renal toxicity plays a key role in rhabdomyolysis-associated kidney damage, [4] and considerable evidence has demonstrated that significant inflammation is involved in the development and progression of rhabdomyolysis-induced AKI. [5] [6] [7] Macrophages, one of the most dominant and widely distributed inflammatory cells, are involved in the initiation and maintenance of acute inflammatory response, [8] and macrophage infiltration into kidney has been found in rhabdomyolysis. Moreover, macrophage depletion ameliorates glycerol-induced AKI in mice. [5, 6] Toll-like receptors (TLRs) are a family of pathogen recognition receptors that play a vital role in the innate immune system. [9, 10] In addition, TLRs are activated by endogenous agonists of nonmicrobial origin and involved in noninfectious inflammatory conditions. [11] TLR4 activation results in the release of nuclear factor-kappa B (NF-κB), allowing NF-κB translocation from cytoplasm to nucleus, where it mediates the increase in cytokine gene expressions leading to proinflammatory responses. [12, 13] However, the role of TLR4/NF-κB in rhabdomyolysis-induced AKI is unclear, in addition to whether or not myoglobin activates the macrophage TLR4/NF-κB pathway. In this study, we used the glycerol-induced AKI model and myoglobin-stimulated macrophage cell line to address these questions and examine potential therapies for rhabdomyolysis-induced AKI.
methods

Animals and drug administration
The animal protocol was approved by the Animal Care and Use Committee of Sichuan University, and all the animal care and experimental procedures were conducted in accordance with The Guide for the Care and Use of Laboratory Animals. C57BL/6 male mice (8-10 weeks old; 25-30 g) were purchased from the Animal Laboratory Center of Sichuan University (Chengdu, China). TLR4 inhibitor CLI-095 and NF-κB inhibitor pyrrolidine dithiocarbamate (PDTC) were purchased separately from InvivoGen, Inc. (San Diego, CA, USA), and Tocris, Inc. (Minneapolis, MN, USA).
After 1 week of adaptation to the housing conditions, the mice were randomly divided into four groups (n = 6 per group): control group, glycerol-treated group, glycerol + CLI-095 group, and glycerol + PDTC group. The mice in the latter three groups were injected with 50% glycerol dissolved in 0.9% normal saline (10 ml/kg) at bilateral back limbs to stimulate the rhabdomyolysis-induced AKI model. The same volume of saline was injected in the mice of control group. To investigate the effect of TLR4 inhibitor and NF-κB inhibitor on rhabdomyolysis-induced AKI, in the glycerol + CLI-095 group, CLI-095 dissolved in dimethyl sulfoxide (DMSO) (Sigma Aldrich, China) at a dosage of 1 mg/ml was injected intraperitoneally 30 min before the injection of glycerol. In the glycerol + PDTC group, 100 mmol/L of PDTC was administered in the same way. The control group received the same volume of saline containing DMSO. The mice were sacrificed at 2 h, 8 h, 24 h, and 48 h after glycerol exposure. Terminal blood samples and kidney tissues were collected for further investigations.
Renal function
Serum creatinine levels (SCr) were evaluated by high-performance liquid chromatography, conducted by the Institute of Drug Clinical Trial and the GCP Center of West China Hospital, to assess renal function. Creatine kinase (CK) was measured in the same way.
Histology
Formalin-fixed, paraffin-embedded kidney sections (4 μm) were stained with hematoxylin and eosin (H&E). Tissue damage was scored on a scale of 0-4, with 0, 1, 2, 3, and 4 corresponding to 0%, <25%, 26-50%, 51-75%, and >76% of injured/damaged renal tubules, respectively. Ten fields of ×40 magnification were examined and averaged. To quantify macrophage infiltration, sections were stained with rat anti-mouse F4/80 antibody (Abcam, Inc., Cambridge, MA, USA) (1:50 dilution). Stained sections were photographed, and five ×40 fields of positive cells were examined for quantitation of macrophage.
Cell culture
Immortalized mouse macrophages (RAW264.7 cell) (ATCC, Rockville, MD, USA) were cultured in RPMI-1640 medium (Hyclone, Inc., Beijing, China), containing 10% fetal bovine serum (Hyclone, Inc., Beijing, China), and incubated at 37°C in a humidified atmosphere of air/CO 2 (95:5). We divided the cells in exponential growth state into four groups: myoglobin-treated group, incubated with 25, 50, 100, and 200 μmol/L ferrous myoglobin for 24 h; myoglobin + CLI-095 group, incubated with CLI-095 at 10 μg/ml 30 min prior to myoglobin treatment; myoglobin + PDTC group, incubated with PDTC at 100 μmol/L 30 min before myoglobin treatment; and control group, cells were incubated with complete medium alone in the control group. Ferrous myoglobin was prepared as described previously. [14] Western blotting analysis Proteins were extracted from renal tissues or cultured cells with a radio immune precipitation lysis buffer (P0013B, Beyotime Biotechnology, China). Samples with equal amounts of total protein (30 mg/ml) were processed for Western blotting, as described previously, [14] using antibodies against TLR4 and NF-κB (Abcam, Cambridge, MA, USA), final dilution 1:500. The ratio of the protein examined was normalized against β-actin. The β-actin antibody and all secondary antibodies were purchased from R&D Systems (MI, USA).
Gene expression quantification
Total RNA was extracted from renal tissues and cultured cells using an RNeasy kit according to the manufacturer's instructions (Takara, Japan). The RNA concentration and purity were confirmed with Nanodrop 2000. The RNA quality was tested by agarose gel electrophoresis followed by cDNA synthesis. Quantitative polymerase chain reaction (qPCR) was performed with the CFX96TM Real-Time System (Bio-Rad, Hercules, USA) and SYBR Premix Ex TaqTM II (Tli RNase H Plus) (Takara). The primers were synthesized by Invitrogen and were as follows: TLR4 (upstream primer) 5'-GGCAGCAGGTCGAATTGTAT-3', (downstream primer) 5'-TCAAGGCTTTTCCATCCAAC-3'; NF-κB (upstream primer) 5'-CGGAATGTGCAGATGCAT-3', (downstream primer) 5'-ACCCCCACTACTCTTGCGGCA-3'; and GAPDH (endogenous control) forward (5'-AGAAGGC TGGGGCTCATTTG-3'), reverse (5'-AGG GGC CATCCACAGTCTTC-3'). Gene expression was analyzed using the 2 −ΔΔCt method by normalizing with GAPDH gene expression in all experiments.
ELISA analysis
Serum and culture supernatants interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α levels were measured using the respective commercially available kits (R&D Systems, Inc., MI, USA) according to the manufacturers' protocols.
Statistical analysis
Data were expressed as mean ± standard deviation. Multiple comparisons of means among groups were examined through one-way analysis of variance; a two-sided P < 0.05 was considered statistically significant. Between-group comparisons of means were analyzed by least significant difference t-tests, and P values were compared to a Bonferroni-corrected significance level of 0.0167 to control the overall significance level for the tests at a family-wise error rate of 0.05. We used SPSS version 19.0 (SPSS Inc., Chicago, IL, USA) for statistical analyses.
results
Toll-like receptor4 inhibitor CLI-095 and nuclear factor-kappa B inhibitor pyrrolidine dithiocarbamate administration suppressed rhabdomyolysis-induced acute kidney dysfunction
As shown in Figure 1a , glycerol injection caused time-dependent kidney dysfunction with increased SCr, and the peak was observed at 24 h (1.09 ± 0.13 mg/dl). Glycerol-induced muscle damage was indicated by increased serum CK levels [t = 14.83, P < 0.0001; Figure 1b] . Respective administration of TLR4 inhibitor CLI-095 and NF-κB inhibitor PDTC significantly ameliorated kidney injury after glycerol injection (t = 15.7, P < 0.0001 and t = 16.11, P < 0.0001). The H&E-stained section showed less tubular necrosis, cast formation, and infiltration of inflammatory cells in the glycerol + CLI-095 and glycerol + PDTC groups as compared to the glycerol-treated group [ Figure 1d] , which was further supported by quantification of the kidney injury score [t = 12.19, P < 0.0001 and t = 11.91, P < 0.0001; Figure 1c ]. 
CLI-095 and pyrrolidine dithiocarbamate downregulated renal Toll-like receptor 4 and nuclear factor-kappa B expression
Twenty-four hours after glycerol injection, the results of Western blotting and reverse transcriptase-qPCR (RT-qPCR) analysis indicated that the expression of TLR4 and NF-κB was significantly increased in glycerol-treated group [P < 0.01; Figure 2 ]. Respective administration of CLI-095 and PDTC reduced the expression of TLR4 and NF-κB in the glycerol + CLI-095 and glycerol + PDTC groups when compared to the glycerol-treated group (P < 0.01).
C L I -0 9 5 a n d p y r r o l i d i n e d i t h i o c a r b a m a t e administration suppressed rhabdomyolysis-induced kidney inflammation
Since previous studies have shown that the TLR4/NF-κB signaling pathway regulates inflammation, [9] [10] [11] whether CLI-095 or PDTC treatment exhibited influence on glycerol-induced proinflammatory cytokine production and macrophage infiltration were investigated. As shown in Figure 3 , glycerol injection significantly increased TNF-α, IL-6, and IL-1β levels in plasma, which was suppressed by CLI-095 or PDTC treatment (P < 0.01). Consistent with the plasma data, macrophage infiltration into the kidney was also inhibited by CLI-095 or PDTC as compared to glycerol treatment [t = 11.21, P < 0.0001; and t = 12.14, P < 0.0001; Figure 4 ].
CLI-095 and pyrrolidine dithiocarbamate downregulated Toll-like receptor 4 and nuclear factor-kappa B expression in macrophage
As shown in Figure 5 , Western blotting and RT-qPCR analysis indicated that myoglobin at 200 μmol/L for 24 h significantly upregulated TLR4 and NF-κB expression in RAW264.7 cells (P < 0.01). Pretreatment with CLI-095 or PDTC effectively lowered TLR4 and NF-κB expression (P < 0.01).
CLI-095 and pyrrolidine dithiocarbamate suppressed myoglobin-induced cytokine excretion in RAW264.7 cells
Ferrous myoglobin-induced proinflammatory cytokine excretion in RAW264.7 cells was suppressed by CLI-095 and PDTC, respectively (P < 0.01). ELISA results showed lower IL-1β, IL-6, and TNF-α levels in the myoglobin + CLI-095 and myoglobin + PDTC groups when compared to the myoglobin-treated group [P < 0.01; Figure 6 ].
dIscussIon
Myoglobin, a key pathogenic factor in rhabdomyolysis-induced AKI, leads to the development and progression of AKI via different mechanisms. [15] It is acknowledged that inflammation plays a major role in rhabdomyolysis-induced AKI. In the rhabdomyolysis-induced AKI mice model, using CLI-095 or PDTC to block TLR4/NF-κB, functional and histologic results showed that the inhibition of TLR4 or NF-κB alleviated glycerol-induced renal damages. CLI-095 or PDTC administration also suppressed proinflammatory cytokine (TNF-α, IL-6, and IL-1β) production and macrophage infiltration into the kidney. Moreover, in an in vitro study, CLI-095 or PDTC suppressed myoglobin-induced expression of TLR4, NF-κB, and proinflammatory cytokine levels in macrophage RAW264.7 cells.
Previous studies revealed that the depletion of the macrophage reduced NF-κB levels and restored the levels of other inflammatory markers. [6] In our study, the results showed that when TLR4/NF-κB was effectively inhibited, glycerol-induced macrophage infiltration into the kidney and proinflammatory cytokine expression was also suppressed. A previous study demonstrated that TLR4 levels were markedly downregulated in rhabdomyolysis-induced AKI kidneys, [16] which contradicted our results. However, as mentioned in that paper, their findings do not exclude increased TLR signaling, as it remained possible that the activity of residual TLR units in AKI kidneys could be enhanced. [16] Further, increased NF-κB expression in rhabdomyolysis-induced AKI kidneys has been observed in previous studies, [17] [18] [19] consistent with our findings, whereas it has been reported that in vitro gene expression of NF-κB showed no significant rise in kidney epithelium cells under 50 μmol/L myoglobin administration. [20] In our study, a higher myoglobin concentration and a different cell line were used. What's more, TLR4/NF-κB has also been found activated in ischemic kidney damage, glomerulonephritis, diabetes nephropathy, and renal allograft rejection. [21] [22] [23] [24] The TLR4 inhibitor and NF-κB inhibitor have been applied to attenuate kidney injury in different models; [25] [26] [27] however, little is known about the effect of the TLR4/NF-κB antagonist on rhabdomyolysis-induced kidney injury, which was clarified by our study.
Both our study and other research have demonstrated that macrophage infiltration was involved in rhabdomyolysis-induced AKI. [5, 6, 9] It has been found that myoglobin prompted tubular cells to secrete macrophage recruiting chemokines, where in response to these chemoattractants, blood monocytes migrated to kidney. In the renal interstitium, myoglobin could directly activate macrophages with the overexpression of the inflammasome component (NLRP3) and proinflammatory factors (IL-1β), [5] which was consistent with our results. Except for macrophage depletion, there was no way reported to block myoglobin-induced proinflammatory cytokine production in macrophage, and our results indicated that TLR4/NF-κB played a role in proinflammatory cytokine production in macrophage.
Above all, in rhabdomyolysis-induced AKI, kidney inflammation is a vicious circle. Inflammatory cells and proinflammatory cytokine, together with intrinsic kidney cells, interacted with each other, thus resulting in the maintenance of a proinflammatory status. Our findings suggested that the pharmacological inhibition of TLR4/NF-κB provides a potential target to break the loop.
In summary, this study indicates that CLI-095 and PDTC exhibit renoprotective effects in the development of rhabdomyolysis-induced AKI, and importantly, pharmacological inhibition of TLR4/NF-κB suppresses macrophage infiltration and proinflammatory cytokine production. This might provide a new therapy for the treatment of rhabdomyolysis-induced AKI.
